Taro-Zoledronic acid injection drug, used for osteoporosis and Page's disease, recalled because it may contain particulate matter
Is your product affected? Check the DIN and lot number on your package against the list in Health Canada's official notice.
See affected DINs and lot numbers on Health Canada ↗Why it was recalled
Product quality
What you should do
- Check your product or contact your pharmacist to determine if it is affected. If you have a recalled product, do not use it and return it to your pharmacy for a replacement product and proper disposal.
- If you have used the recalled product and have health concerns, contact your healthcare provider. Go to the hospital immediately if you develop difficulty breathing, chest pain or confusion.
- Contact Taro Pharmaceuticals Inc. by calling toll free at 1-800-268-1975 if you have questions about this recall.
- Report any health product adverse events or complaints to Health Canada.
Other Recent Recalls
PDP-DIPHENHYDRAMINE
PDP-DIPHENHYDRAMINE 25 MG and 50 MG CAPSULES: Out-of-specification (Impurity)
Type II2026-11-09
Moderate health risk
Unauthorized injectable peptide and non-peptide drugs
Health Canada warns about contaminated unauthorized injectable peptides and non-peptide drugs
2026-11-06
ANTICOAGULANT SODIUM CITRATE SOLUTION, USP
ANTICOAGULANT SODIUM CITRATE SOLUTION, USP 4g/100mL and Potential Bag Leaks
2026-11-03
Recall data is sourced from Health Canada's Recalls and Safety Alerts open dataset. MedShort.ca is an independent tracking tool and does not provide medical advice — for questions about this recall, contact the manufacturer or your pharmacist, or read the full notice linked above.